Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 16, 2026

Is Shell (LSE:SHEL) Still Attractive After A 43% One-Year Share Price Gain?

View original at finance.yahoo.com
“The latest twelve month free cash flow is about US$23.94b. ... SHEL Discounted Cash Flow as at Apr 2026”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Analyst forecasts and Simply Wall St extrapolations indicate free cash flow of US$27.30b in 2030

    60% confidence
  • Shell scores 4 out of 6 on Simply Wall St's valuation checks, suggesting it screens as undervalued on most, but not all, metrics

    60% confidence
  • DCF analysis suggests Shell is undervalued by 54.0% with an estimated intrinsic value of US$72.77 per share compared to current price of £33.46

    60% confidence

Data points we hold from this source

Shell plc · stock return 1w-1.6 percent
Shell plc · stock return ytd21.3 percent
Shell plc · stock return 1y43.0 percent
Shell plc · stock return 1m-2.0 percent
Shell plc · free cash flow23.94 USD
Shell plc · free cash flow forecast27.30 USD
Shell plc · valuation score4 out_of_6
Shell plc · intrinsic value dcf72.77 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Is Shell (LSE:SHEL) Still Attractive After A 43% One-Year Share Price Gain? — Source | Via News | ViaNews Market